Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

ClinicalTrials.gov ID: NCT03672630

Public ClinicalTrials.gov record NCT03672630. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

NTM therapy consists of a multi-drug macrolide based regimen for 18-24 months. Treated patients frequently experience debilitating side effects, and many patients delay the start of antibiotic treatment due to these risks. Common side effects include nausea, diarrhea, and fatigue, and rare but serious toxicities include ocular toxicity, hearing loss, and hematologic toxicity. To date, most of the evidence underlying the current treatment recommendations has come from observational studies in which either a macrolide has been combined with rifampin and ethambutol, or in some cases combined with ethambutol alone. The proposed study will answer whether a third drug is necessary or whether taking two drugs can increase tolerability without a substantial loss of efficacy.

Study identification

NCT ID
NCT03672630
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Kevin Winthrop
Other
Enrollment
474 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 21, 2019
Primary completion
Jan 7, 2026
Completion
Jan 7, 2026
Last update posted
Feb 1, 2026

2019 – 2026

United States locations

U.S. sites
25
U.S. states
18
U.S. cities
24
Facility City State ZIP Site status
Loma Linda University Medical Center Loma Linda California 92354
University of California, San Diego San Diego California 92103
University of California, San Francisco San Francisco California 94110
Stanford University Stanford California 94305
National Jewish Health Denver Colorado 80206
University of Miami Miami Florida 33136
Tampa VA Medical Center Tampa Florida 33612
Emory University Atlanta Georgia 30322
Kaiser Permanente Hawaii Honolulu Hawaii 96817
University of Iowa Iowa City Iowa 52242
University of Kansas Kansas City Kansas 66160
Louisina State University New Orleans Louisiana 70112
Johns Hopkins University Baltimore Maryland 21224
Mayo Clinic Rochester Minnesota 55905
Northwell Health Manhasset New York 11030
New York University New York New York 10016
Columbia University Medical Center New York New York 10032
University of North Carolina Chapel Hill North Carolina 27599
Oregon Health & Science University Portland Oregon 97239
Temple University Philadelphia Pennsylvania 19140
Medical University of South Carolina Charleston South Carolina 29425
University of Texas Health Science Center Tyler Texas 75708
University of Washington Seattle Washington 98104
Vancouver Clinic Vancouver Washington 98664
University of Wisconsin School of Medicine and Public Health Madison Wisconsin 53705

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03672630, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 1, 2026 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03672630 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →